Status:
COMPLETED
Novel Mediators of the Lipodystrophy and Metabolic Consequences of Cushing's Disease
Lead Sponsor:
Columbia University
Collaborating Sponsors:
New York Obesity and Nutrition Research Center
Conditions:
Cushing's Syndrome
Eligibility:
All Genders
18-70 years
Brief Summary
This proposal will evaluate the glucocorticoid mediated changes in body fat distribution and metabolism that occur in patients with Cushing's disease. The objective is to identify the mechanisms that ...
Detailed Description
Cushing's disease (CD) is a disorder of chronic glucocorticoid (GC) excess that gives rise to a constellation of metabolic comorbidities and to a distinct lipodystrophic body habitus characterized by ...
Eligibility Criteria
Inclusion
- Aged 18-70 yrs
- Body mass index (BMI) \<35 kg/m2
- Urine free cortisol (UFC) ≥150ug/d
- Pituitary tumor \>6mm on MRI or an inferior petrosal sinus sampling with central to peripheral plasma adrenocorticotropic hormone (ACTH) gradient
- Normal renal and thyroid function
- HbA1c ≤8.0.
Exclusion
- Smoking
- Alcohol \>2 drinks/day
- Uncontrolled hypertension
- HIV given potential for lipodystrophic confounding
- Pregnancy and nursing
- Use of beta-blockers, β-adrenergic or diabetes medications other than insulin
- History of claustrophobia or difficulty lying flat
- In-dwelling metal hardware.
Key Trial Info
Start Date :
July 16 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 1 2021
Estimated Enrollment :
8 Patients enrolled
Trial Details
Trial ID
NCT03817840
Start Date
July 16 2018
End Date
July 1 2021
Last Update
June 4 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Columbia University Neuroendocrine Unit
New York, New York, United States, 10032